Vectura Group (LON:VEC) had its target price reduced by Royal Bank of Canada from GBX 92 ($1.20) to GBX 88 ($1.15) in a research report sent to investors on Wednesday morning. They currently have a sector performer rating on the stock.
Other equities research analysts have also issued research reports about the stock. Numis Securities reaffirmed a buy rating on shares of Vectura Group in a research note on Thursday, August 23rd. Citigroup reaffirmed a buy rating and set a GBX 155 ($2.02) target price on shares of Vectura Group in a research note on Monday, September 10th. Shore Capital reaffirmed a hold rating on shares of Vectura Group in a research note on Tuesday, September 11th. Finally, Peel Hunt reaffirmed a hold rating on shares of Vectura Group in a research note on Tuesday, September 11th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of GBX 128.11 ($1.67).
Shares of VEC opened at GBX 75.55 ($0.98) on Wednesday. Vectura Group has a 1-year low of GBX 70 ($0.91) and a 1-year high of GBX 166.97 ($2.17).
About Vectura Group
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.